Expression of HLA-G is associated with prognosis in esophageal squamous cell carcinoma

American Journal of Clinical Pathology

Volumn 128, Issue 6, 2007, Pages 1002-1009

  Yie, Shang Mian ^a,b,c   Yang, Hong ^b   Ye, Shang Rong ^c   Li, Ke ^b   Dong, Dan Dan ^b   Lin, Xin Mei ^c  

^a Sichuan Academy of Chinese Medical Science   (China)

^b SICHUAN PROVINCIAL PEOPLE'S HOSPITAL   (China)

^c Chengdu Bioengineering Institute for Cancer Research   (China)

Author keywords

Esophageal squamous cell carcinoma; HLA G; Immunohistochemistry; Prognosis

Indexed keywords

HLA G ANTIGEN; HLA ANTIGEN; HLA ANTIGEN CLASS 1; HLA-G ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; ANTIGEN DETECTION; ANTIGEN EXPRESSION; ARTICLE; CANCER STAGING; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; FOLLOW UP; HISTOLOGY; HUMAN; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; TUMOR LOCALIZATION; ENZYME IMMUNOASSAY; ESOPHAGUS TUMOR; FLUORESCENT ANTIBODY TECHNIQUE; METABOLISM; METASTASIS; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE;

CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; ESOPHAGEAL NEOPLASMS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, DIRECT; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA ANTIGENS; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 38049090570     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/JNCW1QLDFB6AM9WE     Document Type: Article

References (41)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005;55:10-30.
2. Kelsen DP. More or less surgery for esophageal cancer: non-operative therapy of esophageal cancer. Dis Esophagus. 1994;7:162-168.
3. Lewin KJ, Dawsey SM, Wang GQ. Squamous carcinoma of the esophagus in China and the West: are they different disorders? Dis Esophagus. 1995;8:44-47.
4. Roder JD, Stein HJ, Siewert JR. Oesophageal carcinoma. In: Hermaneck P, Gospodarowicz MK, Henson DE, et al, eds. Prognostic Factors in Cancer, UICC. Berlin, Germany: Springer-Verlag; 1995:37-46.
5. Wang DY, Xiang YY, Tanaka M, et al. High prevalence of p53 protein overexpression in patients with esophageal cancer in Linxian, China, and its relationship to progression and prognosis. Cancer. 1994;74:3089-3096.
6. Yoshida K, Kawami H, Yamaguchi Y, et al. Retrovirally transmitted gene therapy for gastric carcinoma using herpes simplex virus thymidine kinase gene. Cancer. 1995;75(6 suppl):1467-1471.
7. Youssef EM, Matsuda T, Takada N, et al. Prognostic significance of the MIB-1 proliferation index for patients with squamous cell carcinoma of the esophagus. Cancer. 1995;76:358-366.
8. Ikeda G, Isaji S, Chandra B, et al. Prognostic significance of biologic factors in squamous cell carcinoma of the esophagus. Cancer. 1999;86:1396-1405.
9. Coggi G, Bosari S, Roncalli M, et al. p53 protein accumulation and p53 gene mutation in esophageal carcinoma: a molecular and immunohistochemical study with clinicopathologic correlations. Cancer. 1997;79:425-432.
10. Kanda Y, Nishiyama Y, Shimada Y, et al. Analysis of gene amplification and overexpression in human esophageal-carcinoma cell lines. Int J Cancer. 1994;58:291-297.
11. Kovats S, Main EK, Librach C, et al. A class I antigen, HLA-G, expressed in human trophoblasts. Science. 1990;248:220-223.
12. Bainbridge DR, Ellis SA, Sargent IL. HLA-G suppresses proliferation of CD4(+) T-lymphocytes. J Reprod Immunol. 2000;48:17-26.
13. Lila N, Rouas-Freiss N, Dausset J, et al. Soluble HLA-G protein secreted by allo-specific CD4+ T cells suppresses the alloproliferative response: a CD4+ T cell regulatory mechanism. Proc Natl Acad Sci U S A. 2001;98:12150-12155.
14. Wiendl H, Mitsdoerffer M, Hofmeister V, et al. A functional role of HLA-G expression in human gliomas: an alternative strategy of immune escape. J Immunol. 2002;68:4772-4780.
15. Le Gal FA, Riteau B, Sedlik C, et al. HLA-G-mediated inhibition of antigen-specific cytotoxic T lymphocytes. Int Immunol. 1999;11:1351-1356.
16. Riteau B, Menier C, Khalil-Daher I, et al. HLA-G1 co-expression boosts the HLA class I-mediated NK lysis inhibition. Int Immunol. 2001;13:193-201.
17. Carosella ED, Moreau P, Le Maoult J, et al. HLA-G molecules: from maternal-fetal tolerance to tissue acceptance. Adv Immunol. 2003;81:199-252.
18. Singer G, Kurman RJ, McMaster MT, et al. HLA-G immunoreactivity is specific for intermediate trophoblast in gestational trophoblastic disease and can serve as a useful marker in differential diagnosis. Am J Surg Pathol. 2002;26:914-920.
19. Ibrahim EC, Aractingi S, Allory Y, et al. Analysis of HLA antigen expression in benign and malignant melanocytic lesions reveals that upregulation of HLA-G expression correlates with malignant transformation, high inflammatory infiltration and HLA-A1 genotype. Int J Cancer. 2004;108:243-250.
20. Bukur J, Rebmann V, Grosse-Wilde H, et al. Functional role of human leukocyte antigen-G up-regulation in renal cell carcinoma. Cancer Res. 2003;63:4107-4111.
21. Urosevic M, Kurrer MO, Kamarashev J, et al. Human leukocyte antigen G up-regulation in lung cancer associates with high-grade, human histology, leukocyte antigen class I loss and interleukin-10 production. Am J Pathol. 2001;159:817-824.
22. Lefebvre S, Antoine M, Uzan S, et al. Specific activation of the non-classical class I histocompatibility HLA-G antigen and expression of the ILT2 inhibitory receptor in human breast cancer. J Pathol. 2002;196:266-274.
23. Urosevic M, Willers J, Mueller B, et al. HLA-G protein up-regulation in primary cutaneous lymphomas is associated with interleukin-10 expression in large cell T-cell lymphomas and indolent B-cell lymphomas. Blood. 2002;99:609-617.
24. Davidson B, Elstrand MB, McMaster MT, et al. HLA-G expression in effusions is a possible marker of tumor susceptibility to chemotherapy in ovarian carcinoma. Gynecol Oncol. 2005;96:42-47.
25. Barrier BF, Kendall BS, Sharpe-Timms K, et al. Characterization of human leukocyte antigen-G (HLA-G) expression in endometrial adenocarcinoma. Gynecol Oncol. 2006;103:25-30.
26. Hansel DE, Rahmanb A, Wilentz RE, et al. HLA-G upregulation in pre-malignant and malignant lesions of the gastrointestinal tract. Int J Gastrointest Cancer. 2005;35:15-24.
27. Chang CC, Campoli M, Ferrone S. HLA class I antigen expression in malignant cells: why does it not always correlate with CTL-mediated lysis? Curr Opin Immunol. 2004;16:644-650.
28. Rebmann V, Regel J, Stolke D, et al. Secretion of sHLA-G molecules in malignancies. Semin Cancer Biol. 2003;13:371-377.
29. Sebti Y, Le Friec G, Pangault C, et al. Soluble HLA-G molecules are increased in lymphoproliferative disorders. Hum Immunol. 2003;64:1093-1101.
30. Nuckel H, Rebmann V, Durig J, et al. HLA-G expression is associated with an unfavorable outcome and immunodeficiency in chronic lymphocytic leukemia. Blood. 2005;105:1694-1698.
31. Ugurel S, Rebmann V, Ferrone S, et al. Soluble human leukocyte antigen-G serum level is elevated in melanoma patients and is further increased by interferon-alpha immunotherapy. Cancer. 2001;92:369-376.
32. Singer G, Rebmann V, Chen YC, et al. HLA-G is a potential tumor marker in malignant ascites. Clin Cancer Res. 2003;9:4460-4464.
33. Ye SR, Yang H, Li K, et al. Human leukocyte antigen G (HLA-G) expression: as a significant prognostic indicator for patients with colorectal cancer. Mod Pathol. 2007;20:375-383.
34. Watanabe H, Jass JR, Sobin LH. Histological Typing of Gastric and Oesophageal Tumours. 2nd ed. Berlin, Germany: Springer-Verlag; 1990.
35. Sobin H, Wittekind C, eds. UICC: TNM Classification of Malignant Tumors. 6th ed. New York, NY: John Wiley; 2002:60-64.
36. Alexander J, Watanabe T, Wu TT, et al. Histopathological identification of colon cancer with microsatellite instability. Am J Pathol. 2001;158:527-535.
37. Greer SE, Goodney PP, Sutton JE, et al. Neoadjuvant chemoradiotherapy for esophageal carcinoma: a meta-analysis. Surgery. 2005;137:172-177.
38. Rouas-Freiss N, Moreau P, Ferrone S, et al. HLA-G proteins in cancer: do they provide tumor cells with an escape mechanism? Cancer Res. 2005;65:10139-10144.
39. Soundararajan R, Rao AJ. Trophoblast "pseudo-tumorigenesis" significance and contributory factors. Reprod Biol Endocrinol. 2004;2:15-27.
40. Sargent IL, Borzychowski AM, Redman CW. Immunoregulation in normal pregnancy and pre-eclampsia: an overview. Reprod Biomed Online. 2006;13:680-686.
41. Malmberg KJ, Levitsky V, Norell H, et al. IFN-gamma protects short-term ovarian carcinoma cell lines from CTL lysis via a CD94/NKG2A-dependent mechanism. J Clin Invest. 2002;110:1515-1523.